Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MANAGEMENT TO HOST CONFERENCE CALL AND WEBCAST AT 4:30 PM ET ON THAT DAY BOCA RATON, FLA, JULY 31, 2026 (GLOBE NEWSWIRE) -- INMUNE BIO INC. (NASDAQ: INMB) (THE COMPANY), A LATE-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON INFLAMMATION AND IMMUNOLOGY, TODAY ANNOUNCED T THAT IT WILL HOST A CONFERENCE CALL ON THURSDAY, AUGUST 6TH, 2026 AT 4:30PM EDT TO DISCUSS RESULTS FOR ITS QUARTER ENDED JUNE 30, 2026 AND TO PROVIDE A CORPORATE UPDATE. CONFERENCE CALL INFORMATION TO PARTICIPATE IN THIS EVENT, DIAL APPROXIMATELY 5 TO 10 MINUTES BEFORE THE BEGINNING OF THE CALL.

INMUNE BIO INC. TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON THURSDAY, AUGUST 6TH

BOCA RATON, FLA., JULY 31, 2026 (GLOBE NEWSWIRE) -- INMUNE BIO INC. (NASDAQ: INMB) (THE COMPANY), A LATE-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON INFLAMMATION AND IMMUNOLOGY, TODAY ANNOUNCED THAT ON JULY 30, 2026, IT RECEIVED A RESEARCH AND DEVELOPMENT CASH REBATE FROM AUSTRALIA OF APPROXIMATELY $4.2 MILLION. THIS REBATE IS IN ADDITION TO APPROXIMATELY $0.4 MILLION OF REBATE FROM THE UNITED KINGDOM DURING JUNE 2026. AFTER ADJUSTING SECOND-QUARTER OPERATING CASH FLOWS TO EXCLUDE THE APPROXIMATELY $0.4 MILLION REBATE RECEIVED DURING THE QUARTER, THE COMBINED REBATE PROCEEDS EXCEEDED THE COMPANY'S NET CASH USED IN OPERATING ACTIVITIES DURING THE QUARTER. THE REBATES STRENGTHEN THE COMPANY'S BALANCE SHEET AND EXTEND ITS CASH RUNWAY AS INMUNE BIO ADVANCES CORDSTROM (EBSTROCEL) TOWARD REGULATORY FILINGS.

INMUNE BIO RECEIVES R&D REBATES OF APPROXIMATELY $4.6 MILLION

GLOBAL EXPERTS IN MSC CLINICAL TRANSLATION TO ADVISE EBSTROCEL REGULATORY AND CLINICAL DEVELOPMENT AND GUIDE EXPANSION OF CORDSTROM PRODUCT OPPORTUNITIES

INMUNE BIO ESTABLISHES SCIENTIFIC ADVISORY BOARD TO SUPPORT LATE-STAGE DEVELOPMENT AND EXPANSION OF CORDSTROM PLATFORM

COMMERCIAL-READY MANUFACTURING NOW SUPPORTS PLANNED PHASE 3 CONFIRMATION TRIAL, AND US, EU AND UK REGULATORY SUBMISSIONS FOR FUTURE COMMERCIAL SUPPLY. COMPANY EXPRESSES SUPPORT FOR MHRA DRAFT RARE DISEASE THERAPIES REGULATORY FRAMEWORK BOCA RATON, FLA, JULY 20, 2026 (GLOBE NEWSWIRE) -- INMUNE BIO INC. (NASDAQ: INMB) (THE COMPANY), A LATE-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON INFLAMMATION AND IMMUNOLOGY, TODAY ANNOUNCED A SIGNIFICANT MANUFACTURING MILESTONE FOR ITS CORDSTROM PLATFORM.

INMUNE BIO COMPLETES COMMERCIAL MANUFACTURING MILESTONE SUPPORTING PLANNED GLOBAL REGISTRATION FILINGS FOR CORDSTROM PLATFORM

THE STUDY POINTS TO SOLUBLE TNF AS A KEY BIOLOGICAL LINK BETWEEN HEAD INJURY AND ALZHEIMER'S DISEASE AND SHOWS THAT SELECTIVELY NEUTRALIZING IT WITH XPRO1595 PREVENTS THE INJURY-INDUCED RISE IN AMYLOID PATHOLOGY WHILE IMPROVING EARLY COGNITIVE AND PAIN-RELATED OUTCOMES.

INMUNE BIO'S XPRO1595 PREVENTS BRAIN-INJURY-INDUCED ALZHEIMER'S PATHOLOGY, MEMORY LOSS, AND PAIN IN NEW PEER-REVIEWED PRECLINICAL STUDY

THE STUDY POINTS TO SOLUBLE TNF AS A KEY BIOLOGICAL LINK BETWEEN HEAD INJURY AND ALZHEIMER'S DISEASE AND SHOWS THAT SELECTIVELY NEUTRALIZING IT WITH XPRO1595 PREVENTS THE INJURY-INDUCED RISE IN AMYLOID PATHOLOGY WHILE IMPROVING EARLY COGNITIVE AND PAIN-RELATED OUTCOMES. BOCA RATON, FL, JULY 15, 2026 (GLOBE NEWSWIRE) -- INMUNE BIO, INC.

INMUNE BIOS XPRO1595 PREVENTS BRAIN-INJURY-INDUCED ALZHEIMER'S PATHOLOGY, MEMORY LOSS, AND PAIN IN NEW PEER-REVIEWED PRECLINICAL STUDY

ADVANCED MRI ANALYSES SHOWED EARLY TREATMENT-RELATED CHANGES IN WHITE MATTER MYELIN INTEGRITY AND CORTICAL MICROSTRUCTURE AT WEEK 24, SUPPORTING BIOLOGIC ACTIVITY OF SELECTIVE SOLUBLE TNF INHIBITION.

INMUNE BIO TO PRESENT POSITIVE PHASE 2 IMAGING DATA FOR XPRO IN EARLY ALZHEIMER'S DISEASE AT AAIC

SECURES GLOBAL FRAMEWORK FOR COMPOSITION-OF-MATTER AND METHOD-OF-TREATMENT CLAIMS COVERING LEAD PROGRAM EBSTROCEL FOR EPIDERMOLYSIS BULLOSA AND NEXT-GENERATION ENGINEERED MODALITIES EXTENDING TO 2045 BOCA RATON, FLA. , JULY 01, 2026 (GLOBE NEWSWIRE) -- -- INMUNE BIO INC. (NASDAQ: INMB) (THE "COMPANY"), A LATE-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON INFLAMMATION AND IMMUNOLOGY, TODAY ANNOUNCED THAT IT HAS SUBMITTED ITS CORDSTROM PLATFORM PATENT APPLICATION INTO THE U.

INMUNE BIO ADVANCES CORDSTROM PLATFORM PATENT APPLICATION IN THE U.S. FOLLOWING FAVORABLE INTERNATIONAL WRITTEN OPINION

APPROVAL OF PEDIATRIC STRATEGY VALIDATES CLINICAL DATA PACKAGE AND ACCELERATES THE REGULATORY PATH FOR CORDSTROM IN THE UNITED KINGDOM

INMUNE BIO INC. ACHIEVES MHRA APPROVAL OF PIP FOR CORDSTROM

MHRA MINUTES FROM MAY 12 PRE-MAA SCIENTIFIC ADVICE MEETING CONFIRM AGREEMENT ACROSS ALL QUESTIONS COVERING CMC, NON-CLINICAL AND CLINICAL EVIDENCE PACKAGES  MHRA PEDIATRIC FEEDBACK RECOGNIZES MISSIONEB PHASE 2 DATA AS DEMONSTRATING CLINICALLY MEANINGFUL SYMPTOMATIC BENEFIT, PARTICULARITY PAIN AND PRURITIS, AND STATES THE DATA COULD SUPPORT POSITIONING AS CHRONIC OR INTERMITTENT SUPPORTIVE THERAPY FOR RDEB BOCA RATON, FLA, JUNE 23, 2026 (GLOBE NEWSWIRE) -- INMUNE BIO INC. (NASDAQ: INMB) (THE COMPANY), A LATE-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON INFLAMMATION AND IMMUNOLOGY, TODAY ANNOUNCED THAT IT HAS RECEIVED OFFICIAL, ACCEPTED MEETING MINUTES FROM ITS RECENT FACE-TO-FACE PRE-MARKETING AUTHORIZATION APPLICATION (PRE-MAA) SCIENTIFIC ADVICE MEETING WITH THE UK MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) FOR CORDSTROM (EBSTROCEL) IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB). THE MAY 12, 2026, MEETING RESULTED IN WRITTEN ALIGNMENT ACROSS ALL QUESTIONS SUBMITTED BY THE COMPANY AND PROVIDES A CLEAR REGULATORY PATH FOR INMUNE BIO'S PLANNED 2026 UK MARKETING AUTHORIZATION APPLICATION (MAA) SEEKING CONDITIONAL MARKETING AUTHORIZATION FOR EBSTROCEL IN RDEB.

INmune Bio, Inc.

INMB

Price

Financial Reports

No items found.

Press Releases

INmune Bio, Inc.

INMB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INMB